CLDN4 and neoplasm: D@C-LP NIRF signals at the tumor site were stronger than those of D@LPs, indicating much greater accumulation of D@C-LPs in tumors compared with D@LPs and supporting strongly enhanced targeting ability of C-LPs compared with LPs in this CLDN4-positive allograft model.